c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.

Abstract:

:1,25-Dihydroxyvitamin D3 (1,25D) induces differentiation of myeloid leukemia cells, but resistant cells are also encountered. We studied the mechanistic basis for the resistance in a model system using enhancers of 1,25D, the antioxidant carnosic acid and a kinase inhibitor SB202190. Knock-down (KD) of JNK2p54 unexpectedly increased the intensity of differentiation induced by the 1,25D, carnosic acid and SB202190 (DCS) combination. This was associated with upregulation of activated JNK1p46, and the transcription factors regulated by the JNK pathway, c-Jun, ATF2 and JunB, as well as C/EBP beta. In contrast, KD of JNK1p46 reduced the intensity of DCS-induced differentiation, and partially abrogated activation of c-Jun/AP-1 transcription factors.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Chen-Deutsch X,Garay E,Zhang J,Harrison JS,Studzinski GP

doi

10.1016/j.leukres.2009.03.003

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

1372-8

issue

10

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(09)00112-X

journal_volume

33

pub_type

杂志文章
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

    abstract::There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2020.106385

    authors: Goldberg AD,Atallah E,Rizzieri D,Walter RB,Chung KY,Spira A,Stock W,Tallman MS,Cruz HG,Boni J,Havenith KEG,Chao G,Feingold JM,Wuerthner J,Solh M

    更新日期:2020-08-01 00:00:00

  • Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

    abstract::Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-pla...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.10.004

    authors: Jain N,Cortes J,Quintás-Cardama A,Manshouri T,Luthra R,Garcia-Manero G,Kantarjian H,Verstovsek S

    更新日期:2009-06-01 00:00:00

  • Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement.

    abstract::Two AML patients, whose leukemic clonogenic cells totally reacted to the anti-lactofucopentaose III S4-7 monoclonal antibody (MoAb), underwent autologous bone marrow transplantation, in first complete remission, after in-vitro purging with S4-7 MoAb and complement. After ablative chemotherapy (BAVC regimen) and reinfu...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(87)90050-6

    authors: Ferrero D,De Fabritiis P,Amadori S,De Felice L,Gallo E,Meloni G,Pregno P,Pulsoni A,Simone F,Tarella C

    更新日期:1987-01-01 00:00:00

  • Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.

    abstract::Increasing evidence suggest that epigenetic mechanisms (e.g. histone modification by histone deacetylases) play a major role in the pathogenesis of Hodgkin's lymphoma (HL). We treated HL cell lines with the histone deacetylase inhibitor vorinostat and investigated the gene expression profile of these cells by using DN...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.02.021

    authors: Kewitz S,Bernig T,Staege MS

    更新日期:2012-06-01 00:00:00

  • Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice.

    abstract::A novel bivalent single chain fusion protein, Bic3, was assembled consisting of the catalytic and translocation domains of diphtheria toxin (DT(390)) fused to two repeating sFv molecules recognizing human CD3 epsilon of the human T-cell receptor. Historically, problems with these constructs include low yield, toxicity...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.08.006

    authors: Vallera DA,Todhunter D,Kuroki DW,Shu Y,Sicheneder A,Panoskaltsis-Mortari A,Vallera VD,Chen H

    更新日期:2005-03-01 00:00:00

  • Activation of Ha-ras in human chronic granulocytic and chronic myelomonocytic leukaemia.

    abstract::DNAs from chronic granulocytic leukaemia (CGL) and chronic myelomonocytic leukaemia (CMML) were assayed for transforming genes by transfection into NIH 3T3 cells. Foci DNA was tagged with a geneticin-resistance cosmid, then followed through a drug selection and tumorigenicity assay. Activated Ha-ras genes, with point ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(88)90033-1

    authors: Gow J,Hughes D,Farr C,Hamblin T,Oscier D,Brown R,Padua RA

    更新日期:1988-01-01 00:00:00

  • Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv(16) chromosome: case report and review of literature.

    abstract::Granulocytic sarcoma (GS) is a rare extra-medullary tumor and usually involves the skin, soft tissue, and lymph nodes. GS is found in 8% of acute myeloid leukemia (AML) patients, especially patients with t(8;21)AML. It has been suggested that GS is a poor prognostic factor in t(8;21)AML. Compared to t(8;21)AML, GS is ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.11.003

    authors: Fujieda A,Nishii K,Tamaru T,Otsuki S,Kobayashi K,Monma F,Ohishi K,Nakase K,Katayama N,Shiku H

    更新日期:2006-08-01 00:00:00

  • Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.

    abstract::Bone marrow specimens from 185 patients with plasma cell disorders (PCD) were investigated by fluorescence in situ hybridization (FISH) in order to determine the temporal sequence of cytogenetic aberrations. In 25 cases combined FISH analysis has also been performed at single cell level. Clonal evolution was observed ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2011.02.010

    authors: Nagy Z,Kajtár B,Jáksó P,Dávid M,Kosztolányi S,Hermesz J,Kereskai L,Pajor L,Alpár D

    更新日期:2011-08-01 00:00:00

  • An autologous tumor vaccine for CLL.

    abstract::Chronic Lymphocytic Leukemia B cells (CLL) are malignant cells which retain at least some functions of normal B cells. Paramount amongst the latter is that when such cells are appropriately stimulated, they are able to present antigens, including any potential tumor antigens, making them excellent choices as a candida...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2018.03.002

    authors: Zhu F,Khatri I,Spaner D,Gorczynski RM

    更新日期:2018-05-01 00:00:00

  • Kappa light chain gene rearrangement in a T-cell lymphoma.

    abstract::Forty-three patients were studied to determine whether light chain gene rearrangements may occur in hematopoietic cells not pertaining to the B-lineage. In only one patient, affected by T-cell lymphoblastic lymphoma, one kappa light chain allele was rearranged. Neither at the protein level nor at the RNA level the rea...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(91)90145-j

    authors: Moretti L,Mariano MT,Donelli A,Montagnani G,Sarti M,Grantini M,Di Prisco U,Torelli U,Narni F

    更新日期:1991-01-01 00:00:00

  • V(H)3-48 and V(H)3-53, as well as V(H)3-21, gene rearrangements define unique subgroups in CLL and are associated with biased lambda light chain restriction, homologous LCDR3 sequences and poor prognosis.

    abstract::This study determined IgV(H) gene usage in 228 chronic lymphocytic leukaemia patients to investigate associations between gene usage and other biological or clinical characteristics. V(H)3-48 [N=8] and V(H)3-53 [N=4] gene rearrangements showed biased lambda light chain restriction and were predominantly found in femal...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.03.028

    authors: Matthews C,Catherwood MA,Morris TC,Alexander HD

    更新日期:2007-02-01 00:00:00

  • Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.

    abstract::Inhibition of cyclooxygenase 2 (COX-2) by the selective COX-2 inhibitor celecoxib has been suggested as potentially useful for B-cell lymphoma therapy. However, additional pharmacological activities of celecoxib have been discovered and have challenged the notion that its antitumor effects are mediated primarily via t...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.09.028

    authors: Chen ST,Thomas S,Gaffney KJ,Louie SG,Petasis NA,Schönthal AH

    更新日期:2010-02-01 00:00:00

  • The expression of PRAME in chronic lymphoproliferative disorders.

    abstract::The PRAME gene encodes an antigen recognized by autologous T lymphocytes and is expressed in trophoblasts, testis and frequently in human solid cancers and acute leukemias, making it a candidate for immunotherapy and for detecting MRD. We demonstrate expression of PRAME by RT-PCR in the peripheral blood or bone marrow...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00217-5

    authors: Proto-Siqueira R,Falcão RP,de Souza CA,Ismael SJ,Zago MA

    更新日期:2003-05-01 00:00:00

  • Genomic instability and rapid clinical course in adult T-cell lymphoma/leukemia patient.

    abstract::Adult T-cell leukemia/lymphoma is a distinct clinical entity characterized by a clonal proliferation of malignant T-lymphocytes. The etiologic agent of the disease is a Human T-cell lymphotropic virus type I. It occurs almost exclusively in areas where the virus is endemic; however the disease develops only in the min...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.02.011

    authors: Zámecníkova A,Al Bahar S,Elshinnawy SE

    更新日期:2010-12-01 00:00:00

  • Immunotherapy in adult acute leukemia.

    abstract::The treatment of acute myeloid leukemia (AML) did not evolve profoundly in the last decades. Some improvement has been made for acute lymphoblastic leukemia (ALL). Emerging new treatment modalities, such as immunotherapy, are now beginning to be available for acute leukemia, mostly for patients suffering from ALL. Thi...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2017.06.011

    authors: Blum S,Martins F,Lübbert M

    更新日期:2017-09-01 00:00:00

  • Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies.

    abstract::Survivin is a newly discovered inhibitor of the apoptosis protein, IAP, expressed during development and in human cancers. The effector cell protease receptor-1 (EPR-1) gene is oriented in the opposite direction on the same DNA double strand. Thus, the Survivin and EPR-1 (Survivin/EPR-1) genes exist in a head-to-head ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(00)00065-5

    authors: Shinozawa I,Inokuchi K,Wakabayashi I,Dan K

    更新日期:2000-11-01 00:00:00

  • Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.

    abstract::We have recently established the MV4-11 acute myelogenous leukemia (AML) subline, designated as MV4-11 TP53 R248W, which possesses a missense mutation (CGG→TGG; R248W) in the TP53 gene, leading to inactivation of this transcription factor. DNA methyltransferase (DNMT) inhibitor 5-Aza-2'-deoxycytidine (5-AzadC) induced...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2011.04.004

    authors: Nishioka C,Ikezoe T,Yang J,Udaka K,Yokoyama A

    更新日期:2011-07-01 00:00:00

  • Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.

    abstract:OBJECTIVE:Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients. We report here our results tes...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.04.006

    authors: Zheng W,Wei G,Ye X,He J,Li L,Wu W,Shi J,Zhang J,Huang W,Xie W,Luo Y,Xue X,Lin M,Huang H,Cai Z

    更新日期:2009-12-01 00:00:00

  • Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.

    abstract::Acute myeloid leukemia is an aggressive disease that arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. Deletions on the long arm of chromosome 9 (del(9q)) are observed in 2% of acute myeloid leukemia patients. Our deletion analysis in a cohort of 31 del(9q) acute myeloid leuke...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2018.11.007

    authors: Naarmann-de Vries IS,Sackmann Y,Klein F,Ostareck-Lederer A,Ostareck DH,Jost E,Ehninger G,Brümmendorf TH,Marx G,Röllig C,Thiede C,Crysandt M

    更新日期:2019-01-01 00:00:00

  • A cytogenetic model predicts relapse risk and survival in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation in morphologic complete remission.

    abstract::Up to 30% of patients with acute myeloid leukemia (AML) and abnormal cytogenetics have persistent cytogenetic abnormalities (pCytAbnl) at morphologic complete remission (mCR). We hypothesized that the prognostic significance of pCytAbnl in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) i...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2014.11.007

    authors: Rashidi A,Cashen AF

    更新日期:2015-01-01 00:00:00

  • The nature of lysosomal enzyme glycosylation in ALL: relevance to abnormal beta-hexosaminidase expression.

    abstract::The glycosylation of beta-hexosaminidase was investigated in the transformed cell-line, CCRF/CEM, derived from a human acute lymphoblastic leukaemia, and comparisons were made with enzyme from normal human skin fibroblasts. A series of studies including neuraminidase sensitivity, lectin chromatography, Biogel P4 chrom...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(88)90146-4

    authors: Moss SE,Besley GT

    更新日期:1988-01-01 00:00:00

  • Aspiration biopsy-nucleic acid diagnosis of thyroid malignant lymphoma by vectorette PCR: experience of eight cases.

    abstract::The usefulness of a new method to detect B-cell monoclonality named VR, which is a combination of the digestion with restriction enzymes and vectorette PCR, in aspiration biopsy-nucleic acid diagnosis (ABND) of thyroid malignant lymphoma was investigated. ABND was performed in 12 patients in whom malignant lymphoma wa...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.03.019

    authors: Takano T,Asahi S,Matsuzuka F,Hidaka Y,Yoshida H,Miyauchi A

    更新日期:2008-01-01 00:00:00

  • Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia.

    abstract::Fluorescent-labeled DNA probes were used to study 52 chronic lymphocytic leukemia (B-CLL) patients for (1) disease progression, (2) angiogenesis genes, (3) T-cell leukemia 1 gene (TCL1), (4) immunoglobulin heavy chain variable region (IGHv) and (5) chromosome 6q. Compared to stable disease, more patients with progress...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.07.012

    authors: Fink SR,Paternoster SF,Smoley SA,Flynn HC,Geyer SM,Shanafelt TD,Lee YK,Jelinek DF,Kay NE,Dewald GW

    更新日期:2005-03-01 00:00:00

  • Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia.

    abstract::The WHO classification of hematological malignancies includes 5q-syndrome as a separate category within myelodysplastic syndromes (MDS). Clinically, patients with 5q-syndrome have a milder disease than patients with other MDS. The basis for this difference is not known. Identifying 5q-syndrome can be difficult because...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00039-5

    authors: Washington LT,Jilani I,Estey E,Albitar M

    更新日期:2002-10-01 00:00:00

  • Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.

    abstract::5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation and an active antileukemic agent, produced an induction of cytidine deaminase activity in human HL-60 myeloid leukemic cells. This increase in enzyme activity correlated with the induction of differentiation of the HL-60 leukemic cells as shown ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(90)90067-j

    authors: Momparler RL,Laliberté J

    更新日期:1990-01-01 00:00:00

  • The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy.

    abstract::We conducted an analysis of the effect of monocytosis at diagnosis of CLL on subsequent overall (OS) and treatment-free survival (TFS). Monocyte counts were performed using the Sysmex XE2100 analyser. A monocyte count >0.9 × 10(9)L(-1) at the time of diagnosis was associated with a shortened OS and TFS. Monocytosis at...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2013.02.020

    authors: Mazumdar R,Evans P,Culpin R,Bailey J,Allsup D

    更新日期:2013-06-01 00:00:00

  • Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS production.

    abstract::Dequalinium (DQA) has been proposed as a selective antitumoral agent due to its preferential accumulation in mitochondria of cancer cells. Our aim was a better understanding of DQA cytotoxicity. DQA-induced NB4 and K562 cell alterations are initiated within the first 30 min of treatment at a high DQA concentration wit...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.11.018

    authors: Sancho P,Galeano E,Nieto E,Delgado MD,García-Pérez AI

    更新日期:2007-07-01 00:00:00

  • ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type.

    abstract::The process of B-cell development is characterized by the activation of the unfolded protein response. Under certain circumstances, the unfolded protein response can be manipulated in a cell death-inducing way. Therefore, tackling the unfolded protein response might be an attractive strategy in the treatment of diffus...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.08.017

    authors: Boelens J,Jais JP,Vanhoecke B,Beck I,Van Melckebeke H,Philippé J,Bracke M,Jardin F,Brière J,Leroy K,Offner F,Lust S

    更新日期:2013-01-01 00:00:00

  • Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.

    abstract::Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2mg/m2 i.v. daily for 5 days as a continuous infusion limits its use in older patients. Therefore, we studied topotecan 1.5mg/m2 per day i.v. over 2 h for three consecutive days in 2...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0145-2126(03)00181-4

    authors: Vaena DA,Walker P,Pennington K,Stephens A,Stender MJ,Yiannoutsos CT,Young C,Stoner C,Cripe LD,Hoosier Oncology Group.

    更新日期:2004-01-01 00:00:00

  • Differentiation of isotope-labeled myeloid leukemia cells free in the peritoneal cavity of syngeneic mice.

    abstract::Ml cells were labeled in vitro with [3H]thymidine and injected into the peritoneal cavity of syngeneic mice. After several days the peritoneal cells were harvested and [3H]labeled cells were determined by autoradiography. The inoculated isotope-labeled Ml cells differentiated in the peritoneal cavity and lipopolysacch...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90050-9

    authors: Honma Y,Hayashi M,Kasukabe T,Hozumi M

    更新日期:1982-01-01 00:00:00